ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, p210-BCR-ABL is a constitutively activated tyrosine kinase that triggers several signaling pathways which collectively confers CML cells a proliferative advantage and resistance to apoptosis [2-5].